Kreztel-Trio Tablet is a combination antihypertensive medication containing Telmisartan 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg, formulated to effectively manage hypertension in patients requiring multiple drug therapy. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure. Amlodipine, a calcium channel blocker, promotes arterial smooth muscle relaxation by inhibiting calcium influx, thereby decreasing peripheral vascular resistance. Hydrochlorothiazide, a thiazide diuretic, facilitates sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to volume reduction and blood pressure lowering. The synergistic action of these agents provides comprehensive blood pressure control by targeting different physiological pathways. Kreztel-Trio is indicated for patients with essential hypertension who require combination therapy to achieve optimal blood pressure targets. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes due to risks of hypotension, electrolyte imbalance, and renal impairment. Contraindications include hypersensitivity to any component, severe renal or hepatic impairment, and pregnancy. Patient adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes.